Founded by Matt Hayward, pharmacist and owner of HL Pharma, the newly launched BS3 offers a state-of-the-art facility for the storage and distribution of pharmaceuticals. ‘Working in the pharmaceutical industry, we were ourselves unable to find suitable temperature-controlled storage and distribution facilities to meet our needs. So BS3 was built to service that gap,’ says Hayward, BS3’s Managing Director.

In addition to fundamental storage solutions, Hayward recognised the need for a qualified and experienced team equipped with extensive knowledge of Good Distribution Practice of medicines, as well as advanced security systems. Given their own expertise including highly specialised legal compliance knowledge required for all Scheduled Medicines, Hayward and his team decided to build the solution themselves. Their boutique facility offers purpose-built systems designed to meet all current and growing needs with an ability to adapt to each client’s unique requirements.

Located in Melbourne, this all-new facility can accommodate human and veterinary pharmaceutical medicines and devices. This includes Schedule 2, 3 and 4 medicines as well as controlled drugs and prohibited substances that fall into Schedules 8 and 9. Clients will find refrigerated storage options at 2 to 8 degrees Celsius for Schedule 8 products, as well as general facilities for products needing to be stored between 15 and 25 degrees Celsius. Additionally, BS3 offers high-end security systems and vaulted storage facilities equipped with video surveillance – a requirement for storage of Schedule 8 and 9 products.

BS3 can also provide the specialised transportation capabilities necessary to distribute Scheduled Medicines.

The BS3 team has extensive experience working within the pharmaceutical, retail, customer service, wholesale, distribution and cold storage sectors in Australia, Europe and the U.S. Working alongside director Matt Hayward are Stephanie Gunn, Head of Quality, and Emily Hovette, Head of Commercial Operations.

For further information, media enquiries or interview requests contact:

Stephanie Gunn T: 03 7036 0065 | E: